Pfizer Jumps After Journal Publishes Weight-Loss Pill Data

Pfizer Inc.’s experimental pill helped people with diabetes lose weight in published results from a short-term trial that were also presented at a conference in Europe last fall.

Pfizer gained as much as 4.7% as of 12:38 p.m. in New York, the most intraday since November, a sign of how eager the market is for news about weight-loss drugs, such as Wegovy from Danish Novo Nordisk A/S. The data appeared in Jama Network Open.

In the trial in 411 patients, those who got the highest dose of the Pfizer’s danuglipron lost 4.17 kilograms (9.3 pounds) more weight over ...